This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Andrew Geall, PhD
Co-founder and Chief Development Officer at Replicate Bioscience


Dr. Andrew Geall is the Chief Development Officer at Replicate Bioscience and cofounder of the company. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions. Prior to joining Replicate, Dr. Geall was Chief Scientific Officer at Precision NanoSystems Inc. (1 year). He has also held positions as Vice President of Formulations, Analytics and Chemistry at Avidity Biosciences (5 years), where he helped pioneered the development of their antibody-oligonucleotide conjugate delivery platform. Prior to Avidity, he led the mRNA vaccines Platform in the Vaccine division of Novartis (7 years). During his tenure, he created a global team and was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines.

Agenda Sessions

  • Panel Discussion: mRNA Therapies – The Next Chapter

  • Interim Phase 1 Clinical Data from a 2nd Generation Self-replicating RNA Vaccine for Infectious Disease: Immune Responses and Efficacy at All Dose Levels (0.1, 1.0 and 10 mcg) with a Clean Safety Profile